Outcomes of systemic targeted therapy in recurrent renal cell carcinoma treated with adjuvant sunitinib.

Guillermo de VelascoÁlvaro Ruiz-GranadosOscar ReigFrancesco MassariMiguel Angel Climent DuranElena VerzoniJeffrey GrahamRoberto LlarenaMichele De TursiFrede DonskovClara IglesiasHardev S PandhaXavier Garcia Del MuroGiuseppe ProcopioStephane Marie OudardDaniel CastellanoLaurence Albiges

Published in: BJU international (2021)

Rechallenge with sunitinib or other systemic therapies is still a feasible therapeutic option that provides patients with advanced or metastastic RCC with additional clinical benefits with regard to PFS and OS after failed response to adjuvant sunitinib.

Keyphrases

renal cell carcinoma
early stage
type diabetes
newly diagnosed
drug induced